Join to View Full Profile
450 Massachusetts Ave Nw"#608"Washington, DC 20001
Phone+1 973-722-4058
Are you Dr. Madan?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Ravi Madan, MD is an oncologist in Washington, District of Columbia. He is currently licensed to practice medicine in New Jersey.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2005 - 2009
Rutgers Health/New Jersey Medical SchoolResidency, Internal Medicine, 2001 - 2005- Rutgers New Jersey Medical SchoolClass of 2001
Certifications & Licensure
NJ State Medical License 2004 - 2025
Publications & Presentations
PubMed
- Defining The Role for Hormone Therapy in Biochemically Recurrent Prostate Cancer: What Counts as a Win for Patients?Lauren O'Loughlin, Melissa L Abel, Ravi A Madan, David J Einstein
Current Oncology Reports. 2025-03-01 - Reply to B. Tombal et al.David J Einstein, Meredith M Regan, Julia S Stevens, David F McDermott, Ravi A Madan
Journal of Clinical Oncology. 2024-11-20 - 1 citationsProgression-free survival end points in prostate cancer: are we truly making progress.Ravi A Madan, Edwin M Posadas, Richard J Lee
Nature Reviews. Urology. 2024-11-01
Authored Content
- 'Inside ODAC’s Vote on Sotorasib in Advanced and Metastatic NSCLC: LessonsNovember 2023
Press Mentions
FDA’s ODAC: Risks Outweigh Benefits for Checkpoint Inhibitors in Some CancersSeptember 30th, 2024- No Benefit for PD-1 Inhibitors in Certain Gastroesophageal Cancers, FDA Panel SaysSeptember 27th, 2024
- PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate CancerOctober 12th, 2023
- Join now to see all
Grant Support
- Microfluidic isolation and molecular analysis of circulating tumor cells for the study of neuroendocrine transdifferentiation in prostate cancerMASSACHUSETTS GENERAL HOSPITAL2022–2027
